Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Show me how to use this page

Epigenomics AG Stock

Price
Target price
-

-

-
-
-
-
 
WKN: A3H218 / Name: Epigenomics / Stock / ? /
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Epigenomics AG in the next few years
Wizard

Epigenomics AG Stock

What does Epigenomics do?

Pros and Cons of Epigenomics AG in the next few years

Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
B****
Cons
?
S********** s********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Your Opinion
Legal notice

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-06-12

Upon first glance at the financials of Epigenomics, it appears that the company has experienced significant fluctuations in its key financial metrics over the past several years, warranting further analysis to arrive at a comprehensive understanding of the company's financial health.

Increasing Total Assets: Epigenomics' total assets have demonstrated a substantial increase from €6,797,000 in 2020 to €24,663,000 in 2021. This trend indicates that the company has been able to grow its asset base, which may be favorable for future business ventures.

Stable Gross Profit: Despite varying revenue figures, the company has managed to maintain relatively stable gross profit margins. This suggests that Epigenomics has a degree of control over its cost of revenue.

Show more

Comments

systinvest hat das Wertpapier Epigenomics AG in seinem Wikifolio Aktienwertselektion mit System gekauft.
Show more

systinvest 
0
Report Share
04.01.22 Buy -37.06%
Show more
Not a member yet? Sign up for free!